Hydrogenics (HYGS) Hits New 52-Week High at $9.09

Hydrogenics Co. (NASDAQ:HYGS) (TSE:HYG)’s share price hit a new 52-week high on Wednesday . The company traded as high as $9.09 and last traded at $9.05, with a volume of 6032 shares. The stock had previously closed at $8.32.

HYGS has been the topic of a number of recent research reports. Canaccord Genuity initiated coverage on Hydrogenics in a research note on Wednesday, January 16th. They set a “speculative buy” rating and a $8.75 target price on the stock. Roth Capital lowered Hydrogenics from a “buy” rating to a “neutral” rating and set a $7.00 target price on the stock. in a research note on Wednesday, January 30th. ValuEngine lowered Hydrogenics from a “buy” rating to a “hold” rating in a research note on Monday, March 25th. HC Wainwright increased their target price on Hydrogenics from $7.50 to $9.00 and gave the stock a “buy” rating in a research note on Monday, March 18th. Finally, Zacks Investment Research lowered Hydrogenics from a “hold” rating to a “sell” rating in a research note on Wednesday, March 6th. One research analyst has rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the company’s stock. Hydrogenics presently has a consensus rating of “Hold” and a consensus price target of $8.25.

The stock has a market capitalization of $164.26 million, a PE ratio of -10.47 and a beta of 0.83.

Hydrogenics (NASDAQ:HYGS) (TSE:HYG) last issued its quarterly earnings results on Tuesday, May 14th. The energy company reported ($0.15) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.02). The company had revenue of $8.08 million for the quarter, compared to analyst estimates of $9.55 million. Hydrogenics had a negative return on equity of 81.90% and a negative net margin of 39.35%. On average, equities research analysts forecast that Hydrogenics Co. will post -0.43 EPS for the current year.

A number of large investors have recently modified their holdings of the stock. Renaissance Technologies LLC grew its position in Hydrogenics by 15.7% during the first quarter. Renaissance Technologies LLC now owns 16,750 shares of the energy company’s stock worth $133,000 after buying an additional 2,270 shares in the last quarter. NJ State Employees Deferred Compensation Plan grew its position in Hydrogenics by 11.1% during the first quarter. NJ State Employees Deferred Compensation Plan now owns 40,000 shares of the energy company’s stock worth $317,000 after buying an additional 4,000 shares in the last quarter. Finally, Emancipation Management LLC grew its position in Hydrogenics by 43.1% during the fourth quarter. Emancipation Management LLC now owns 37,200 shares of the energy company’s stock worth $186,000 after buying an additional 11,200 shares in the last quarter. 16.49% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Hydrogenics (HYGS) Hits New 52-Week High at $9.09” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be accessed at https://sportsperspectives.com/2019/05/15/hydrogenics-hygs-hits-new-52-week-high-at-9-09.html.

About Hydrogenics (NASDAQ:HYGS)

Hydrogenics Corporation, together with its subsidiaries, designs, develops, and manufactures hydrogen generation products based on water electrolysis technology; and fuel cell products based on proton exchange membrane technology. It operates in two segments, OnSite Generation and Power Systems. The OnSite Generation segment develops products for industrial gas, hydrogen fueling, and renewable energy storage markets.

Read More: What are the reasons investors use put options?

Receive News & Ratings for Hydrogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hydrogenics and related companies with MarketBeat.com's FREE daily email newsletter.